Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 8/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indigotindisulfonate SCHEMBL2727226 | 1.00 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL29387846 | 1.00 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL5455215 | 1.00 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL186297 | 1.00 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3652418 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3680504 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL29694234 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL186296 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL9107944 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3960977 | 0.96 | CA12 (0.47) | CA12CA1CA2CA9CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398826-A1 | PHARMACEUTICAL FORMULATION | HOFFMANN-LA ROCHE INC. (US) | 2024-12-05 | — | — | US | claimed |
| US-12083127-B2 | Pharmaceutical formulation | HOFFMANN-LA ROCHE INC. (US) | 2024-09-10 | — | — | US | claimed |
| US-20230390302-A1 | PHARMACEUTICAL FORMULATION | HOFFMANN-LA ROCHE INC. (US) | 2023-12-07 | — | — | US | claimed |
| US-20230054407-A1 | OPTICAL BIOPSY STAIN PANELS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-02-23 | — | — | US | claimed |
| EP-4082535-A1 | PHARMACEUTICAL FORMULATION | F. Hoffmann-La Roche AG (CH) | 2022-11-02 | — | — | EP | claimed |
| EP-3720424-B1 | PHARMACEUTICAL FORMULATION | HOFFMANN LA ROCHE (CH) | 2022-09-21 | — | — | EP | claimed |
| EP-3720424-A1 | PHARMACEUTICAL FORMULATION | H. Hoffnabb-La Roche Ag (CH) | 2020-10-14 | — | — | EP | claimed |
| US-20200297732-A1 | PHARMACEUTICAL FORMULATION | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | claimed |
| WO-2019110723-A1 | PHARMACEUTICAL FORMULATION | F. HOFFMANN-LA ROCHE AG (CH) | 2019-06-13 | — | — | WO | claimed |
| EP-4712785-A1 | CHEWABLE COMPOSITIONS COMPRISING PECTIN AND UROLITHIN | Amazentis SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12576064-B2 | Urolithin gummy (pectin) formulations | AMAZENTIS SA (CH) | 2026-03-17 | — | — | US | disclosed |
| US-20250381253-A1 | MUTANASES AND ORAL CARE COMPOSITIONS COMPRISING SAME | NOVOZYMES A/S (DK) | 2025-12-18 | — | — | US | disclosed |
| US-20250375412-A1 | UROLITHIN GUMMY (PECTIN) FORMULATIONS | AMAZENTIS SA (CH) | 2025-12-11 | — | — | US | disclosed |
| US-20250367159-A1 | UROLITHIN GUMMY (PECTIN) FORMULATIONS | AMAZENTIS SA (CH) | 2025-12-04 | — | — | US | disclosed |
| EP-0132472-A1 | Medicated products containing a magnesium trisilicate adsorbent with a medicament drug adsorbed thereon | WARNER-LAMBERT COMPANY (US) | 1985-02-13 | — | — | EP | disclosed |
| US-4499001-A | DENTURE CLEANER | WARNER-LAMBERT COMPANY (US) | 1985-02-12 | — | — | US | disclosed |
| US-4409118-A | Tablet forming cleanser composition and method of preparation | WARNER-LAMBERT COMPANY (US) | 1983-10-11 | — | — | US | disclosed |
| US-4388328-A | WITH MANNITOL AND SACCHARIN | WARNER-LAMBERT COMPANY (US) | 1983-06-14 | — | — | US | disclosed |
| US-4362639-A | OXIDIZERS, BLEACHES | WARNER-LAMBERT COMPANY (US) | 1982-12-07 | — | — | US | disclosed |
| US-4012250-A | Imaging system | XEROX CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576064-B2 | Urolithin gummy (pectin) formulations | PYGM, HAGH, GYS1 | CA12 3554/4885CA1 4404/4885CA2 3811/4885 |
| US-20230390302-A1 | PHARMACEUTICAL FORMULATION | CYP4B1, GABRA5, CYP2C8 | CA12 3789/4885CA1 3791/4885CA2 1748/4885 |
| US-20250375412-A1 | UROLITHIN GUMMY (PECTIN) FORMULATIONS | PYGM, GALE, GYS1 | CA12 1553/4885CA1 3141/4885CA2 1890/4885 |
| US-20250367159-A1 | UROLITHIN GUMMY (PECTIN) FORMULATIONS | PYGM, GALE, GYS1 | CA12 1553/4885CA1 3141/4885CA2 1890/4885 |
| US-20240398826-A1 | PHARMACEUTICAL FORMULATION | GRIK5, GABRA5, HTR5A | CA12 4334/4885CA1 3797/4885CA2 3385/4885 |
| US-12083127-B2 | Pharmaceutical formulation | HTR1A, HTR5A, HTR1D | CA12 3979/4885CA1 2537/4885CA2 4185/4885 |
| US-20200297732-A1 | PHARMACEUTICAL FORMULATION | CYP4B1, GABRA5, CYP2C8 | CA12 3789/4885CA1 3791/4885CA2 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.